Highlights from ACG2025
Focus on Metabolic Dysfunction–Associated Steatohepatitis (MASH, formerly NASH)
DAY 3: Resmetirom Shows Promising Results in Patients with Cirrhosis
Patients with well compensated cirrhosis related to metabolic dysfunction-associated steatohepatitis (MASH) achieved significant reductions in liver stiffness, fibrosis biomarkers and scores, and portal hypertension over 2 years of treatment with resmetirom, according to data from a 2-year open-label trial. Naim Alkhouri, MD shared results from the trial at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona.
November 7, 2025
Read more
DAY 3: Lean Individuals Are Not Exempt from Steatotic Liver Disease or Its Complications
A meta-analysis presented at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona showed that lean individuals may develop metabolic dysfunction-associated steatotic liver disease (MASLD) and associated complications, although they are at a lower risk for these conditions than people with higher BMI, who are classified as overweight.
November 7, 2025
Read more
DAY 3: The 3S Approach to Managing Metabolic Dysfunction-Associated Steatohepatitis: Screen, Stage, Start Therapy
In the era of targeted therapies for metabolic dysfunction-associated steatohepatitis (MASH), inaction is not an option for healthcare providers who manage patients with this condition, according to Naim Alkhouri, MD, chief academic officer at Summit Clinical Research and director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, Ohio.
November 7, 2025
Read more
DAY 3: Dual Agonists Increase Cardiometabolic Protection for Patients with Steatotic Liver Disease and Diabetes
New data presented at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona showed that dual agonist tirzepatide was more effective than semaglutide in improving cardiovascular outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, and type 2 diabetes.
November 7, 2025
Read moreMore Summaries
DAY 1: Treatment with Resmetirom May Prevent Cognitive Decline in Patients with Metabolic Dysfunction-Associated Steatohepatitis
The benefit of resmetirom treatment may extend beyond liver fat reduction and a decrease in metabolic risk, as evidenced by an exploratory analysis that showed gains in cognitive function and quality of life for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), treated with this medication. The results were presented in a poster session at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona.
November 5, 2025
Read more
DAY 1: Electronic Care Pathway Improves Screening of Patients at High Risk for Hepatic Fibrosis
Use of a clinical pathway integrated into the electronic health record (EHR) in combination with provider education improved screening for metabolic dysfunction-associated steatohepatitis (MASH) at an academic primary care clinic, according to an analysis presented at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona.
November 5, 2025
Read more
DAY 1: Higher Doses of Semaglutide Boost Resolution of Metabolic Dysfunction-Associated Steatohepatitis
Metabolic dysfunction-associated steatohepatitis (MASH) is a rapidly growing public health concern driven by the global epidemics of obesity, type 2 diabetes, and dyslipidemia. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant benefits in reducing weight and preventing cardiovascular events in individuals with metabolic dysfunction.
November 5, 2025
Read more
DAY 1: Thrombocytopenia May Be an Early Predictor for the Onset of Cirrhosis In Metabolic Dysfunction-Associated Steatohepatitis
Declining platelet levels may provide important clues regarding the onset of cirrhosis in people diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), according to findings presented at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona.
November 5, 2025
Read more
DAY 1: Incretin-Based Therapies Mark a Significant Shift in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
A meta-analysis presented at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona showed that incretin-based dual and triple agonists have the potential to elevate the level of care for patients with metabolic dysfunction-associated steatohepatitis (MASH) by delivering significant improvements in hepatic and metabolic outcomes.
November 5, 2025
Read more
DAY 2: Resmetirom Benefit Extends Beyond Resolution of Steatohepatitis in People with Type 2 Diabetes
Patients with type 2 diabetes mellitus who were treated with resmetirom for metabolic dysfunction-associated steatotic liver disease (MASLD) experienced significant improvements in lipid profiles and liver enzymes, according to a multicenter propensity-matched analysis. Lead author Regis Lee, DO, an internal medicine specialist at the HCA Healthcare Riverside Community Hospital in Riverside, California, noted that patients with diabetes achieved greater improvements compared with their counterparts without diabetes, reflecting potentially distinct metabolic and hepatic responses to resmetirom in this population. Lee presented the results of the analysis at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona.
November 6, 2025
Read more
DAY 2: Glucagon-Like Peptide-1 Receptor Agonists May Change the Course of Metabolic Liver Disease
New data presented at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona highlight the potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in changing the natural history of metabolic dysfunction-associated steatohepatitis (MASH) by reversing hepatic fibrosis.
November 6, 2025
Read more
DAY 2: Non-Invasive Tools Provide New Options for Detecting Fibrosis in Clinical Practice
Non-invasive tests (NITs) may facilitate screening and staging of hepatic fibrosis in clinical practice, enabling providers to monitor progression of metabolic dysfunction-associated steatohepatitis (MASH) without the use of invasive liver biopsies, according to a meta-analysis featured at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona.
November 6, 2025
Read more
DAY 2: Efruxifermin Proves Superior to Placebo in Reversing Metabolic Dysfunction-Associated Steatohepatitis
A meta-analysis presented at the 2025 Annual Scientific Meeting of the American College of Gastroenterology in Phoenix, Arizona suggests that efruxifermin may emerge as a promising targeted therapy with the potential to improve hepatic fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH).
November 6, 2025
Read more
© 2025 Wolters Kluwer. All right reserved.